AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Century Casinos, Inc.
Video analysis: CNTY
All videosNo video analysis for this stock yet. Request one from our team.
News: CNTY
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D® Clinical & Research Congress 2026 highlighting CNTY-813 Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion™ 5.0 into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026 PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights. "We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D.
Century Casinos, Inc. (CNTY) Q2 2026 Earnings Call Transcript
Century Casinos, Inc. (CNTY) Q2 2026 Earnings Call Transcript
Century Casinos (CNTY) Reports Q2 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.4 per share a year ago.
Century Casinos, Inc. Announces Second Quarter 2026 Results
All-Time Record Q2 Net Operating Revenue and Adjusted EBITDAR, Driven by Strong Performance in North America. COLORADO SPRINGS, Colo.
Century Casinos Announces Dates of Second Quarter 2026 Earnings Release and Conference Call
COLORADO SPRINGS, Colo., July 30, 2026 /PRNewswire/ -- Century Casinos, Inc. (Nasdaq Capital Market®: CNTY) announced today that the Company will release its earnings for the second quarter 2026 on Friday, August 7, 2026.
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:
Despite Fast-paced Momentum, Century Casinos (CNTY) Is Still a Bargain Stock
Century Casinos (CNTY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is Century Casinos (CNTY) Outperforming Other Consumer Discretionary Stocks This Year?
Here is how Century Casinos (CNTY) and Carter's (CRI) have performed compared to their sector so far this year.
